MIMETAS develops Organ-on-a-Chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic platform, designated OrganoPlate™, enables testing of compounds in high-throughput on miniaturized organ models. These models translate better to the human situation as compared to laboratory animals and conventional cell culture models. MIMETAS value proposition is a build-up of 4 phases:
Phase 1. Organ-on-a-Chip development
MIMETAS develops and validates customized disease- and tissue models for pre-clinical testing. Currently, Mimetas works with most major pharmaceutical companies on the development of kidney, gut, brain, liver and blood vessel models.
Phase 2. OrganoPlate™ sales
MIMETAS produces and sells the OrganoPlate™. The OrganoPlate™ platform supports 3D cell culture under continuous perfusion. The plate is ideally suited for growing miniature tubes, such as blood vessels and kidney tubes and enables multi-cell-type co-culture, without usage of artificial membranes
Phase 3. Pre-grown Organ-on-a-Chip models
MIMETAS aims to disruptively change the cell-based assay market, by offering a panel of pre-grown organ-models of unprecedented physiological relevance in a ready-to-use format. MIMETAS will expand its offering with pre-grown versions of the models developed in phase 1.
Phase 4. Personalized medicine
MIMETAS aims to offer a phenotypic alternative to genotyping for personalized therapy selection. The OrganoPlate™ platform will be used to select best possible therapies for individual patients, based on a tissue material from that same patient. The oncology field will be a first focus. The OrganoPlate™ and its organ models are targeting the market for 3D tissue culture. The biggest buyers in this market are the preclinical research and screening departments of pharmaceutical companies. Next in line are the toxicology departments of major food and chemicals companies.
In addition, the OrganoPlate™ is actively marketed to academic research groups and biotech companies. This market segment has strategic value to showcase the unique capabilities of the platform and develop novel applications. The personalized medicine market is currently largely served by molecular biology solutions, such as next-generation sequencing and microarrays. With the PhenomePlate™, MIMETAS aims to revolutionize this market by using an individual patient’s diseased cells rather than molecular fingerprints to select the optimal therapy for that specific patient.
The market for personalized medicine is dominated by institutions for medical care and health insurance companies. Also the pharmaceutical industry sees this as a strategic direction. Addressing this market requires intensive interaction with regulatory institutions.
Jos Joore is a biotech entrepreneur with over 14 years of executive level bio-business experience. He held positions within biotech companies Pepscan, Skyline Diagnostics, Kreatech and Westburg. Jos hold a masters degree in Biology, a PhD in Developmental Biology and a cum laude masters degree in Business Marketing
View Jos Joore’s profile on LinkedIn
Paul Vulto has extensive international experience in Lab-on-a-Chip technology and business. In the past twelve years, he held positions in Japan, Italy, Germany and the Netherlands. Paul was involved in the companies Silicon Biosystems, Ayanda Biosystems and ScienceWorks prior to founding MIMETAS. Paul holds a cum laude masters degree in Biomedical Engineering and a cum laude PhD degree in Microsystems Engineering.
View Paul Vulto’s profile on LinkedIn
Providing personalized advise on medicine through our organ-on-a-chip.
Make personalized medicine for real for everyone.
Preventing unnecessary side effects, improving anti-cancer therapy efficacy, save expenses on cancer drugs that have no clinical benefit.
- How can we capture the qualitative Value for the well being of patients with regards to the usage of Organ-on-a-Chip What main components should a potential business case for medical doctors and insurance companies contain in order to support the usage of Organ-on-a-Chip?
- How do you build your policy making around ‘patient well being’ in order to support these type of solutions?
- What are ways and criteria for a new sustainable business model for health solutions aimed at the well being of patients who’s health can improve by medicine?